cagrilintide trial Novo Nordisk: Can CagriSema Show 25% Weight Loss In REDEFINE-1 Trial? Cagrilintide produced 10.8 percent body

Given the ICD10 diagnosis codes (R79.0, Z79.899, R53.83, Z13.220, E11.43, G62.9, I83.813, I10, E78.2, E66.01, M62.838, M54.9, M25.512, L68.0, M25.562, Z13.29, E28.2, G47.9) and the laboratory tests (IGF1, progesterone, FSH, TPO antibody, homocysteine, reverse T3 LC/MS/MS, CRP, DHEA LC/MS, comprehensive metabolic panel, CBC with differential, estradiol, hemoglobin A1c, lipid panel with calculated LDL, vitamin D 25OH, insulin, ferritin/iron/transferrin/TIBC, free testosterone, random cortisol, total testosterone, free T3, free T4, TSH, vitamin B12), which diagnosis codes can be used to justify billing for each lab test?

Nancy W

CagriSema submitted for FDA approval in December 2025 with expected approval in Q4 2026 or Q1 2027, meaning launch around mid-2027

Complete blood cell counts remained within normal limits for all samples taken on days 0, 7, and 14, suggesting that topical applications of TCC and zinc oxide did not result in systemic abnormalities

Tier 2: Partial Documentation Acceptable with Caution Criteria partially met: HPLC purity shown but no MS confirmation, in-house lab only, or COA not batch-specific